Summary Information:
Atea Pharmaceuticals Inc. Common Stock
NASDAQ:AVIR


email
[email protected]
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Atea Pharmaceuticals Inc. Common Stock
Exchange: NASDAQ
Symbol: AVIR
SEC CIK: 0001593899
Phone: 857-204-8109
125 SUMMER STREET
16TH FLOOR
BOSTON MA 02110
CEO:
Price when page updated: 2.925 Date: 2023-11-30
Company Website:
ateapharma.com

_Description: Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, the Company has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, the Company is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) infection, and respiratory syncytial virus (RSV).

IPO YEAR:
2020
Sector:
Consumer Durables
Industry:
Specialty Chemicals
ADRTSO:

MarketCap:
244048876.00
Beta:
0.03093601732885199
52 Week High:
94.17
52 Week Low:
7.37
52 Week Change:
-0.7357888631090488
Short Interest:

Short Date:

Shares Outstanding:
83102730
Dividend Rate:
0
Dividend Yield:
0.00%
ExDividend Date:

Latest EPS:

Latest EPS Date:
14 Nov 2022
Float:
0
return on Equity:
-
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
N/A
ttmEPS:
0
Revenue:
$423.264M
Gross Profit:

Cash:

Debt:

Institution Percent:
48.50%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
0.70%
Return on Assets:
-
Return on Capital:

Profit Margin:
-
Price to Sales:
-
Price To Book:
2.74
Short Ratio:
3.96
PE Ratio:
0
Employees:
39
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__Atea Pharmaceuticals Inc. Common Stock [ AVIR ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-11-30